DNMT3A and acute myeloid leukemia: In patients with de novo AML, FLT3‐ITD (55.0% vs. 87.7%, P = .002) or DNMT3A (62.5% vs. 87.3%, P = .013) mutations remained an unfavorable factor predicting a lower rate of CR compared with the absence of these gene mutations (Table S8).